Article
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
11 Mar 2021
Abstract excerpt
Currently, no effective therapies exist for fibrodysplasia ossificans progressiva (FOP), a rare congenital syndrome in which heterotopic bone is formed in soft tissues owing to dysregulated activity of the bone morphogenetic protein (BMP) receptor kinase ALK2 (also known as ACVR1). From a screen of known biologically active compounds, we identified saracatinib as a potent ALK2 kinase inhibitor. In enzymatic and...
Topics
Join the communities discussing this publication.